GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Gross Margin %

Scancell Holdings (FRA:SCP) Gross Margin % : 0.00% (As of Oct. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Scancell Holdings's Gross Profit for the six months ended in Oct. 2023 was €0.00 Mil. Scancell Holdings's Revenue for the six months ended in Oct. 2023 was €0.00 Mil. Therefore, Scancell Holdings's Gross Margin % for the quarter that ended in Oct. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Scancell Holdings's Gross Margin % or its related term are showing as below:

FRA:SCP' s Gross Margin % Range Over the Past 10 Years
Min: 90.04   Med: 90.04   Max: 90.04
Current: 90.04


During the past 13 years, the highest Gross Margin % of Scancell Holdings was 90.04%. The lowest was 90.04%. And the median was 90.04%.

FRA:SCP's Gross Margin % is ranked better than
86.6% of 746 companies
in the Biotechnology industry
Industry Median: 59.74 vs FRA:SCP: 90.04

Scancell Holdings had a gross margin of N/A% for the quarter that ended in Oct. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Scancell Holdings was 0.00% per year.


Scancell Holdings Gross Margin % Historical Data

The historical data trend for Scancell Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Gross Margin % Chart

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 90.04

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 90.04 - -

Competitive Comparison of Scancell Holdings's Gross Margin %

For the Biotechnology subindustry, Scancell Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Gross Margin % falls into.



Scancell Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Scancell Holdings's Gross Margin for the fiscal year that ended in Apr. 2023 is calculated as

Gross Margin % (A: Apr. 2023 )=Gross Profit (A: Apr. 2023 ) / Revenue (A: Apr. 2023 )
=5.4 / 5.986
=(Revenue - Cost of Goods Sold) / Revenue
=(5.986 - 0.596) / 5.986
=90.04 %

Scancell Holdings's Gross Margin for the quarter that ended in Oct. 2023 is calculated as


Gross Margin % (Q: Oct. 2023 )=Gross Profit (Q: Oct. 2023 ) / Revenue (Q: Oct. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Scancell Holdings  (FRA:SCP) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Scancell Holdings had a gross margin of N/A% for the quarter that ended in Oct. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Scancell Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (FRA:SCP) Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines